G-DEFINER

Page related to the project Gender Difference in sidE eFfects of ImmunNotherapy: a possibile clue to optimize cancEr tReatment (G-DEFINER)

[G-DEFINER @GDefiner]

@Dr_Alex_Eustace @ProfJohnCrown @News_IACR @DCU @AACR @EACRnews @IrishCancerSoc @BreakthroCancer @DcuBiotech @DCUFSH @CCRTIreland Congratulations to @ProfJohnCrown!!!

[Sandro Pasquali @sandro_pasquali]

#Postdoc position available on #sarcoma #Immunity at Molecular Pharmacology of @IstTumori - if interested please contact [email protected]

[G-DEFINER @GDefiner]

https://t.co/Xr3L1zcwmB

[G-DEFINER @GDefiner]

@GENDER_NET_Plus @Dr_Alex_Eustace @karolinskainst @DCU @IstTumori @svuh @alba_mici

[G-DEFINER @GDefiner]

@GENDER_NET_Plus @Dr_Alex_Eustace @karolinskainst @DCU @IstTumori @svuh @IstTumori

[G-DEFINER @GDefiner]

https://t.co/h9JyKCnkqJ

[GENDER-NET Plus @GENDER_NET_Plus]

@GDefiner project investigated the #gender inequalities among #cancer patients in the development of immune-related adverse events associated with #immunotherapy treatment across 4 countries 🇮🇹🇸🇪🇳🇴🇮🇪 Presentation of study outcomes👉📺 https://t.co/WoN3FsR970

[G-DEFINER @GDefiner]

@Dan_Salvatore Fantastica notizia!!

[G-DEFINER @GDefiner]

Delighted to meet at closing meeting of @GDefiner and @GENDER_NET_Plus . Great meeting and lots of results to come!

[G-DEFINER @GDefiner]

https://t.co/sRZwHt7UGm

[G-DEFINER @GDefiner]

https://t.co/uevDq0VCGs

[Frank Harrell @f2harrell]

@ElleLettMDPhD Yes; categorization completely arbitrary; quintiles are demographic not biologic; hides any steep part of the risk curve. Outer quintiles are very heterogeneous. Show the risk curve as a function of relative food volume. #bbrcourse #rmscourse https://t.co/K3jo6IkOlj

[G-DEFINER @GDefiner]

https://t.co/tY4u0VqOmm

[Giacomo G Baldi @GiacomoGBaldi]

Interesting discussion about adjuvant treatment in extremity STS at ISG annual meeting…food for thoughts and new idea for an upcoming trial! Stay tuned…@alegronchi @annamariafrezza @SilviaStacchia @casali_pg @apdeitos @sandro_pasquali @Robertasanfili @ctosociety

[BRIDGES2022 @bridges2022]

Abstract submission is now open for #BRIDGES2022!
The conference BRIDGES BETWEEN DISCIPLINES: GENDER IN STEM AND SOCIAL SCIENCES is a hybrid (on-site + online) event to be held on September 12-16, 2022. More information: https://t.co/2aphmVs2sB
#Intersectionality #GenderBias

[G-DEFINER @GDefiner]

https://t.co/37TdWmGReC

[GENDER-NET Plus @GENDER_NET_Plus]

Dear Twitter, listen to 🇮🇪 🇮🇹🇳🇴🇸🇪@GDefiner coordinator Ros @AlbaMiceli and find out more on #Cancer therapy and sex & #gender inequalities in immune-related adverse events with immunotherapy treatment 👇 RT welcome 📣
https://t.co/GNfm8vBYTA

[G-DEFINER @GDefiner]

https://t.co/71UfTWa6FX

[Retraction Watch @RetractionWatch]

“Female researchers are more read and less cited because they more often engage in research for societal progress.”
https://t.co/Wg0zXAXMJx

[G-DEFINER @GDefiner]

@DCalleMD 😂

[G-DEFINER @GDefiner]

https://t.co/p1hesGUnti

[Alex J Eustace @Dr_Alex_Eustace]

@ProfJohnCrown @GDefiner identifying how gender plays a role in how people have adverse immune related events associated with their immunotherapy.

[G-DEFINER @GDefiner]

https://t.co/I6b88zgbmV

[ProfJohnCrown @ProfJohnCrown]

Is there a way we can make the immunotherapy results in metastatic uveal melanoma better? @Dr_Alex_Eustace and the @CCRTIreland team are also trying to explain gender differences in immunotherapy as part of the international @G-Definer study.

[G-DEFINER @GDefiner]

https://t.co/Ku12tzEgh9

[ProfJohnCrown @ProfJohnCrown]

We are also collaborating with other international colleagues on the G-Definer study looking at gender differences in immunotherapy outcomes. @Dr_Alex_Eustace is leading our effort here.